Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.

PURPOSE To develop a three-dimensional (3D) segmentation and computerized volumetry technique for use in the assessment of neurofibromatosis and to assess the ability of this technique to aid in the calculation of tumor burden in patients with neurofibromatosis types 1 and 2 (NF1 and NF2, respectively) and schwannomatosis detected with whole-body magnetic resonance (MR) imaging. MATERIALS AND METHODS Institutional review board approval and written informed consent were obtained for this prospective HIPAA-compliant study. Fifty-two subjects (27 women, 25 men; mean age, 42 years +/- 15 [standard deviation]; age range, 24-86 years) underwent whole-body MR imaging performed with coronal short inversion time inversion-recovery (STIR) sequences. Whole-body tumor burden was estimated with a 3D segmentation method (the dynamic-threshold [DT] level set method) in 29 subjects (16 with NF1, six with NF2, and seven with schwannomatosis) in whom at least one nerve sheath tumor was reliably identified on MR images. Fifty tumors (25 plexiform and 25 discrete tumors) were randomly selected and subjected to manual and computerized volumetry to assess reliability. Ten plexiform tumors 5 cm or larger in diameter were retrospectively selected and segmented with three initialization methods for computerized volumetry and manually contoured by three radiologists to assess repeatability. Bland-Altman analysis was performed, and intraclass correlation coefficients (ICCs) were calculated. RESULTS A total of 398 nerve sheath tumors (185 plexiform and 213 discrete tumors) were identified in 29 subjects. Volumetric measurements obtained with the computerized method and manual contouring were highly correlated (r(ICC) = 0.99). Bland-Altman analysis showed that computerized volumetry had a mean difference of -2.6% compared with manual volumetry. The repeatability coefficient of the computerized scheme was +/-5% compared with +/-30% for manual contouring. CONCLUSION This 3D segmentation and computerized volumetry technique is reliable relative to manual segmentation and has the advantage of being less labor intensive and more repeatable. This technique can be paired with whole-body MR imaging to determine tumor burden in patients with neurofibromatosis. SUPPLEMENTAL MATERIAL http://radiology.rsnajnls.org/cgi/content/full/250/3/665/DC1

[1]  G. Harris,et al.  Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. , 2008, Neurosurgery.

[2]  Richard C. Pais,et al.  Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. , 2004, Academic radiology.

[3]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[4]  J. Woodruff.  Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. , 1999, American journal of medical genetics.

[5]  K. Hopper,et al.  Analysis of interobserver and intraobserver variability in CT tumor measurements. , 1996, AJR. American journal of roentgenology.

[6]  E. Van Cutsem,et al.  Size quantification of liver metastases in patients undergoing cancer treatment: reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT. , 1997, Radiology.

[7]  Jan M Friedman,et al.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. , 2008, Neuro-oncology.

[8]  P. Ruggieri,et al.  Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 , 2003, Neurology.

[9]  D. Altman,et al.  Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.

[10]  L. Broemeling,et al.  Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Condon,et al.  Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? , 2005, AJNR. American journal of neuroradiology.

[12]  R. Zimmerman,et al.  Plexiform neurofibromas in NF1: toward biologic-based therapy. , 2002, Neurology.

[13]  Tina Young Poussaint,et al.  Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas. , 2003, AJR. American journal of roentgenology.

[14]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[15]  N. Holalkere,et al.  Dynamic-threshold level set method for volumetry of porcine kidney in CT images in vivo and ex vivo assessment of the accuracy of volume measurement. , 2007, Academic radiology.

[16]  R. Arceci,et al.  Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jeffrey Solomon,et al.  Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. , 2004, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[18]  E. Zackai,et al.  Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994. , 1997, The Journal of pediatrics.

[19]  Yasuhiro Inoue,et al.  Localization and trafficking of membrane-bound MMPs , 2001 .

[20]  T. MacDonald,et al.  Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. , 2007, Pediatric neurology.

[21]  S. Steinberg,et al.  NF1 plexiform neurofibroma growth rate by volumetric MRI , 2007, Neurology.

[22]  E. A. Chiocca,et al.  Diagnostic criteria for schwannomatosis , 2005, Neurology.